PG125 ESTABLISHING THE RELATIONSHIP BETWEENTHE ULCERATIVE COLITIS DISEASE ACTIVITY INSTRUMENT (UCDAI) AND PATIENT HEALTH RELATED QUALITY OF LIFE FROM A LARGE RANDOMISED CONTROLLED TRIAL
2008
OBJECTIVES: Alternative treatments are available to relieve
people with moderate and severe psoriasis in states of remission
and relapse. The purpose of this study was characterise treatment
satisfaction with alternative therapies in a survey across
nine European countries. Specifically, to determine relative
treatment satisfaction with etanercept. METHODS: Up to 120
subjects with moderate or severe psoriasis were identified in
each of nine countries: Austria (n = 50), France (n = 120),
Germany (n = 120), Italy (n = 120), The Netherlands (n = 75),
Norway (n = 43), Spain (120), Sweden (n = 50) and the UK
(n = 120). Patients were identified through their dermatologist,
and selected in order to give a sample that represented the alternative
current treatment regimens, including: biologics such as
etanercept, systemic therapies, and light therapy (PUVA).
Patients were excluded if they had psoriatic arthritis. Treatment
severity was classified in two ways. Firstly, self-reported severity,
and secondly; percent bodily coverage with psoriatic
plaques. Satisfaction with treatment was defined as a response
of either “satisfied” or “very satisfied” with treatment. Treatments
were excluded from the analysis where <20 observations
were available. Fumaderm was excluded as it was not relevant
for all countries. RESULTS: There were 818 respondents in
total; 45% male. Their mean age was 40.1 years (sd 11.8), and
the median time since diagnosis was 12.0 years (IQR 4.0 to
21.0). The frequency of psoriasis severity for people with <3%,
3%–10%, and >10% bodily coverage was 74 (9%), 421
(52%), and 323 (39%) people, respectively. Overall, 67% of
people expressed satisfaction with psoriasis treatment (64%
moderate and 71% severe; p = 0.117). For people with moderate
psoriasis, 3% to 10% coverage, the following percent of
people reported satisfaction with treatment: cyclosporine 60%
(52 of 87), PUVA 63% (54 of 86), methotrexate 65% (53 of
81) and etanercept 78% (21 of 27; p = 0.387). For people with
severe psoriasis, >10% coverage, treatment satisfaction was
achieved as follows: methotrexate 59% (31 of 53), PUVA 62%
(28 of 45), cyclosporine 70% (19 of 27), remicade 71% (20 of
28) and etanercept 94% (46 of 49; p = 0.001). People with
severe psoriasis were more satisfied with treatment with etanercept
than moderate psoriasis (78% vs. 94%; p = 0.088).
These findings were consistent across the nine countries. CONCLUSIONS:
The majority of people with moderate and severe
psoriasis expressed satisfaction with their current treatment.
Treatment satisfaction with etanercept in both groups was
more frequent when using etanercept (78% and 94%,
respectively).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI